|
Catalogue
Number
|
Product
|
Order number / Unit
|
|
|
99433
|
PSMA-1007 reference standard
|
99433.0005: 5 mg per vial
99433.0010: 10 mg per vial
Please inquire for customized
filling and bulk quantities.
|
|
|
Reference Standard for [18F]PSMA-1007
|
|
|
Research Chemical
|
|
|
|
|
|
Molar Mass: 1031.00
|
|
|
C49H55FN8O16
|
|
|
CAS-RN not yet assigned
|
|
|
|
|
|
Colourless to off-white solid packaged in dark glass screw cap vials.
|
|
|
|
|
|
|
|
|
Purity: > 95 %
|
|
|
Certificates:
CoA; 1H and 19F NMR spectra (identity); HPLC (purity)
|
|
|
Chemical Name:
(3S,10S,14S)-1-(4-(((S)-4-carboxy-2-((S)-4-carboxy-2-(6-fluoronicotinamido)butanamido)butanamido)methyl)phenyl)-3-(naphthalen-2-ylmethyl)-1,4,12-trioxo-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid
|
|
|
Synonymes:
[18F]PSMA-1007 standard
|
|
|
Literature:
Giesel F.L. et al. 18F-*PSMA-1007* PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. Clin. Genitourin. Cancer. 2016. doi: 10.1016/j.clgc.2016.12.029.
|
|
|
Giesel F.L. F-18 labelled *PSMA-1007*: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2017, 44(4), 678-688. doi: 10.1007/s00259-016-3573-4.
|
|
|
Cardinale J. et al. Preclinical Evaluation of [18F]PSMA-1007: A New PSMA-Ligand for Prostate Cancer Imaging. J. Nucl. Med. 2016. doi: 10.2967/jnumed.116.181768
|
|
|
Giesel F.L. et al. 18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur. J. Nucl. Med. Biol. 2016, 43, 1929-30.
|
|
|
Kesch C. et al. Intra-individual comparison of 18F-PSMA-1007-PET/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer - a retrospective, proof of concept study. J Nucl Med. 2017 doi: 10.2967/jnumed.116.18923
|
|
|
date of product catalogue issue:
10 May 2017
|